FAQ/Help |
Calendar |
Search |
Today's Posts |
04-07-2013, 02:38 AM | #1 | |||
|
||||
Member
|
Adenosine A2A receptor antagonist istradefylline reduces daily off time in Parkinson's disease.
http://www.ncbi.nlm.nih.gov/pubmed/23483627 Abstract BACKGROUND: We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson's disease patients with motor complications in Japan. METHODS: A total of 373 subjects were randomized to receive placebo (n = 126), istradefylline 20 mg/day (n = 123), or istradefylline 40 mg/day (n = 124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated. RESULTS: The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (-0.99 hours, P = .003) and istradefylline 40 mg/day (-0.96 hours, P = .003) groups compared with the placebo group (-0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%). CONCLUSIONS: Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa
__________________
Sim00 Born in 1969, diagnosed PD in 2007, first symptoms 2004. DBS in July 2016. |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Inhaled dopamine agonist clinical trial results | Parkinson's Disease | |||
Simpler Language, More Access to Results Sought for Clinical-Trial Volunteers | Parkinson's Disease | |||
Clinical trial of diabetic drug for Parkinson's disease | Parkinson's Disease | |||
CLINICAL TRIAL: Improve Speech Using an In-the-Ear Device in Parkinson's Disease | Parkinson's Disease Clinical Trials | |||
GDNF clinical trial results | Parkinson's Disease |